Latest Medicine stories from Life.
Capricor Therapeutics has raised concerns about Nippon Shinyaku and its U.S. branch regarding the implementation of a treatment for Duchenne muscular dystrophy.
Recent findings highlight the potential of nanoparticles in fighting drug-resistant cancer, offering new hope for improving chemotherapy outcomes through advanced treatment methods.
Today's biotech news highlights a lawsuit concerning Duchenne therapy and challenges faced by FDA Commissioner Marty Makary in relation to the White House.
This brief outlines the GENEROUS model and explores various elements that may influence Medicaid drug costs, emphasizing the importance of confidentiality regarding certain model details.
A recent study indicates that lubiprostone, a medication typically used for constipation, may play a role in slowing the progression of chronic kidney disease in patients.
Energy Fuels is positioning itself as a key player in the nuclear energy sector with a diverse portfolio that includes uranium, rare earth elements, and medical isotopes.
Researchers from the University of Michigan and MD Anderson Cancer Center have developed a novel nanoparticle therapy that may enhance cancer immunotherapy's safety and efficacy.
Recent developments suggest that a political appointee may be obstructing the approval process for a Sanofi drug, raising alarms about potential political interference at the FDA.
Sanofi has requested the FDA to withdraw teplizumab from its fast-track review program following internal disagreements regarding the drug's approval.
Following a surprising rejection, the FDA will revisit the treatment for a rare cancer, as the developers of Ebvallo have reached an agreement to tackle the concerns raised.
In a significant move within the pharmaceutical industry, Angelini Pharma has announced its acquisition of Catalyst Pharmaceuticals, a company specializing in treatments for rare diseases, for $4.1 billion.
The Trump administration's recent actions regarding drug policy appear inconsistent, as the White House endorses treatment methods while imposing new restrictions.
La Trobe scientists have made a pivotal discovery in the fight against dangerous drug-resistant bacteria.
As discussions around pharmaceutical pricing evolve, the 'Most Favored Nation' model emerges as a potential solution worth considering for its implications and benefits.
In a notable move, Sanofi has requested the FDA to withdraw its type 1 diabetes drug from the expedited review process, citing political interference as a key factor.
The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a substantial ad campaign aimed at the 340B drug discount program, highlighting its budget and focus.
Cytokinetics' heart disease treatment Myqorzo, which has prior approval for one indication, has now successfully met efficacy targets in a Phase 3 trial for a genetic heart condition.
Johnson & Johnson is proceeding with its inflammatory bowel disease therapy, even though recent trials did not demonstrate a statistically significant benefit for patients.
This editorial examines the collaboration between the U.S. government and Gavi, the Vaccine Alliance, focusing on their efforts to enhance immunization access in lower-income countries.
A recent discussion highlights medical students' views on the integration of preventive care education in their curriculum, revealing concerns about coherence in their training.